KOSDAQCosmetics092730

NeopharmCO

₩21,550▼ 0.23%2026-11-18 close
Market Cap
₩345.4B
Turnover
₩200M
Volume
8.2K
Shares out.
16M
PER
11.8×
PBR
1.6×
EPS
₩1,837
Dividend Yield
3.47%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩750 per share · Prices as of the 2026-11-18 close

01

Report overview

Export growth meets an earnings check

NeopharmCO posted sales growth for three consecutive years from 2023 to 2025 and reached KRW 43.6 billion in revenue in the second quarter of 2026, but net income attributable to controlling shareholders fell in the third quarter, making the earnings trend the next item to verify.

  1. 1

    On a disclosed basis, revenue rose from KRW 85 billion in 2022 to KRW 132.2 billion in 2025, and operating profit reached KRW 28.8 billion in 2025, above the 2022 level.

  2. 2

    Third-quarter 2026 revenue was KRW 39.4 billion, up 22.3% year on year, and operating profit was KRW 10 billion, up 48.4%, while net income attributable to controlling shareholders was KRW 4.94 billion, down 28.0%.

  3. 3

    LS Securities said exports in the second quarter of 2026 rose 50.0% to KRW 8.7 billion, with shipments to the United States up 65.1%.

  4. 4

    The advertising and promotional expense ratio rose to 13.1% in the same quarter from 9.5% a year earlier, yet the operating margin still improved 0.5 percentage point to 22.5%.

  5. 5

    The next checkpoints are the preliminary fourth-quarter 2026 results in late January 2027 and the 2026 annual report due around late March 2027.

02

Business structure

Founded in 2000, NeopharmCO is a sensitive-skin cosmetics specialist built around its own brands, including Atopalm, Zeroid, Real Barrier and Dermavie. As of the end of August 2026, the sales mix was reported at 81% domestic and 19% exports.

Second-quarter 2026 sales by channel were KRW 12.3 billion online, KRW 22.6 billion offline and KRW 8.7 billion exports on a consolidated basis, according to an LS Securities report.

Exports rose 50.0% in the same quarter, with shipments to the United States up 65.1% and other regions up 89.0%, so the export base is broadening.

LS Securities estimated strong growth for Zeroid and higher Olive Young sales, and estimated that Real Barrier sales at Daiso rose sharply on wider SKU listings and store-wide ordering. The company's earnings commentary states that Atopalm has ranked first in the sensitive skincare segment for 20 consecutive years.

Marketing spend also increased, with the advertising and promotional expense ratio at 13.1% in the second quarter of 2026 versus 9.5% a year earlier. In September 2025, Yuanta Securities cited an expansion into medical aesthetics through domestic hospital distribution as a new business.

OEM sales have been shrinking, and Hana Securities said in its first-quarter 2025 analysis that this decline helped gross profit by shifting mix toward higher-margin own brands.

Competition centers on brand rivalry within the sensitive and dermo-cosmetics category, where the company overlaps with larger listed peers such as Amorepacific and LG H&H.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩32.2B₩6.8B21.0%
2025Q4₩36.4B₩7.2B19.8%
2026Q1₩36.2B₩8.7B24.0%
2026Q2₩43.6B₩9.8B22.5%
2026Q3₩39.4B₩10B25.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩85B₩21.4B₩17B25.2%12.0%9.2%
2023₩97.1B₩25.3B₩23.2B26.1%14.5%10.9%
2024₩119B₩24.7B₩23.1B20.7%13.0%8.8%
2025₩132.2B₩28.8B₩27.8B21.8%14.2%11.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 85 billion in 2022 to KRW 97.1 billion in 2023 (up 14.2% year on year), KRW 119 billion in 2024 (up 22.6%) and KRW 132.2 billion in 2025 (up 11.1%), and it has increased for three consecutive years from 2023 through 2025.

Operating profit was KRW 21.4 billion in 2022, KRW 25.3 billion in 2023 (up 18.0%), KRW 24.7 billion in 2024 (down 2.6%) and KRW 28.8 billion in 2025 (up 16.7%).

In 2024 revenue grew 22.6% while operating profit declined, and the operating margin fell from 26.1% in 2023 to 20.7% in 2024 before recovering to 21.8% in 2025.

Net income attributable to controlling shareholders rose from KRW 17 billion in 2022 to KRW 23.2 billion in 2023 (up 36.3%), eased to KRW 23.1 billion in 2024 (down 0.6%) and reached KRW 27.8 billion in 2025 (up 20.6%).

In the disclosed tables, net income for each year from 2022 through 2025 carries the same amount as net income attributable to controlling shareholders. Operating cash flow was KRW 18.2 billion in 2022, KRW 23.3 billion in 2023, KRW 18.6 billion in 2024 and KRW 28.4 billion in 2025.

The debt-to-equity ratio was 11.5% at the end of 2025, up from 9.2% in 2022, with total liabilities of KRW 22.5 billion and total equity of KRW 195.4 billion.

Quarterly revenue went from KRW 32.2 billion in the third quarter of 2025 to KRW 36.4 billion in the fourth quarter (up 13.0% quarter on quarter), then KRW 36.2 billion in the first quarter of 2026 (down 0.5%) and KRW 43.6 billion in the second quarter (up 20.3%).

Third-quarter 2026 revenue of KRW 39.4 billion fell 9.6% from the prior quarter but rose 22.3% from a year earlier. Operating profit rose for four consecutive quarters, from KRW 6.77 billion in the third quarter of 2025 to KRW 10 billion in the third quarter of 2026.

Net income attributable to controlling shareholders peaked at KRW 8.62 billion in the first quarter of 2026, then fell for two consecutive quarters to KRW 8.41 billion in the second quarter and KRW 4.94 billion in the third quarter.

The gap between third-quarter operating profit and net income widened, and the preliminary pre-tax profit released on November 9, 2026 was KRW 6.319 billion. That preliminary figure was an internal settlement before external audit review and may change after review.

Because reports described the basis for quarterly results as either consolidated or separate after the subsidiary liquidation in the first quarter of 2026, quarter-on-quarter comparisons should account for any basis difference.

05

Industry analysis

NeopharmCO is a mid-sized cosmetics company anchored in the sensitive-skin and dermo-cosmetics category, with a brand scale and business structure that differ from the large listed peers in the sector.

In its August 2026 report, LS Securities said export growth and structural growth in the dermo-cosmetics category would sustain earnings momentum. On the channel side, LS Securities pointed to Olive Young and exports as the main drivers of high growth.

It estimated that Real Barrier sales at Daiso rose sharply on wider SKU listings and store-wide ordering. Hana Securities said in a 2025 analysis that overseas distribution was widening from an Amazon-centered base into offline retail.

Kolmar Korea and Cosmax operate mainly on an ODM and OEM basis, whereas NeopharmCO is increasing the weight of its own brands. Hana Securities also said in its first-quarter 2025 analysis that the shrinking OEM business, combined with growth in higher-margin brand sales, supported profitability.

The industry backdrop combines the growth of K-beauty exports with changes in domestic retail channels. For the company, the relative growth of domestic offline channels such as Olive Young and Daiso versus overseas online channels centered on Amazon determines its competitive position.

Atopalm carries the company's leadership in sensitive skincare, while medical aesthetics is the main candidate for category extension.

06

Outlook

In its August 2026 report, LS Securities raised its second-half earnings estimates and judged that export growth and structural growth in dermo-cosmetics would sustain earnings momentum.

The same report said that the shift of Amazon Prime Day timing from the third quarter of 2025 to the second quarter of 2026 could create a base effect in the third quarter of 2026, but noted that follow-up marketing ran into early July.

In Investing.com's aggregation, second-quarter 2026 revenue came in above the estimate, while third-quarter revenue fell short. Yuanta Securities said in September 2025 that the company was moving from moisturizer-centered skincare toward a professional brand segment through medical aesthetics.

The contribution of this new business is hard to isolate from reported results, so whether it appears in quarterly sales is the point to check. Exports grew at high rates to both the United States and other regions, and the export share stood at roughly 20% in the second quarter of 2026.

With the advertising expense ratio higher, whether export growth translates into a stable operating margin is the key question for the coming quarters. The preliminary fourth-quarter 2026 results are expected around late January 2027, following a release on January 27, 2026 a year earlier.

The 2026 annual report will show the full-year operating margin and whether the preliminary third-quarter figures changed after audit review.

07

Valuation

PER
11.8×
PBR
1.6×
ROE
14.6%
EPS
₩1,837
BPS
₩13,171
Dividend per share
₩750

The combined net income attributable to controlling shareholders over the last four quarters, KRW 28.7 billion, is above the full-year 2025 figure of KRW 27.8 billion. Market capitalization is above the controlling shareholders' equity of KRW 195.4 billion, so the stock trades at a premium to book value.

In a September 2025 report, Yuanta Securities said the company's price-to-earnings ratio was below the sector average. In a January 2022 report, KB Securities set scenario target multiples ranging from about 10 times on the low side to about 18 times on the high side.

These figures serve as a reference for the historical earnings-multiple band. In an August 10, 2026 report, LS Securities raised its target price to KRW 30,000 and said it applied a 12 times target multiple to earnings.

Because brokers apply different multiples and earnings bases, valuation readings vary by date and assumption. When comparing the current multiple with the historical band, the earnings basis for the same period should be matched.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Fast-growing exports and overseas channels

According to LS Securities, exports in the second quarter of 2026 rose 50.0% to KRW 8.7 billion, with shipments to the United States up 65.1%. The same report said the export base is spreading beyond the United States.

A higher export share spreads revenue exposure across more channels, reducing reliance on any single domestic channel.

Top-line growth and channel diversification

Revenue in 2025 reached KRW 132.2 billion, above KRW 85 billion in 2022, and rose for three consecutive years from 2023 through 2025. LS Securities assessed second-quarter 2026 revenue of KRW 43.6 billion as the highest quarterly sales on record.

Online sales of KRW 12.3 billion and offline sales of KRW 22.6 billion grew together, broadening the channel base.

Financial capacity and cash generation

Total equity at the end of 2025 was KRW 195.4 billion, and total liabilities were KRW 22.5 billion. Operating cash flow in 2025 reached KRW 28.4 billion, up from KRW 18.2 billion in 2022. Net income attributable to controlling shareholders over the last four quarters totaled KRW 28.7 billion.

09

Bear factors

Third-quarter net income decline

Net income attributable to controlling shareholders was KRW 4.94 billion in the third quarter of 2026, down 41.2% from the prior quarter and down 28.0% from a year earlier. It has declined for two consecutive quarters since the first-quarter 2026 peak.

Operating profit rose to KRW 10 billion over the same period, widening the gap between operating and net profit.

Marketing cost pressure

The advertising and promotional expense ratio reached 13.1% in the second quarter of 2026, up from 9.5% a year earlier. In 2024 revenue rose 22.6% while operating profit fell 2.6%. Whether marketing spending converts into sales will determine the direction of the operating margin.

Quarterly revenue volatility

Third-quarter 2026 revenue of KRW 39.4 billion fell 9.6% from the prior quarter, after a 0.5% decline in the first quarter. In Investing.com's aggregation, third-quarter revenue fell short of the estimate. LS Securities pointed to a base effect from the shift in Prime Day timing.

10

Risk factors

Channel and platform dependence

Growth has been driven by specific retail channels such as Olive Young, online platforms and Daiso, so changes in channel policy or listing terms could affect the revenue trend. LS Securities cited Olive Young and exports as drivers of high growth in the second quarter of 2026. Given that overseas sales were centered on Amazon, platform risk remains a factor to monitor.

Disclosure basis and preliminary figures

The third-quarter 2026 figures are preliminary and predate external audit review, so they may change after settlement. Following the liquidation of a subsidiary in the first quarter of 2026, reports described the basis for quarterly results as either consolidated or separate. Differences in basis affect how quarterly growth rates should be read.

Marketing and cost structure

The advertising and promotional expense ratio rose to 13.1% in the second quarter of 2026, adding cost pressure on the operating margin. If advertising efficiency declines, the margin could fall. The drop in the operating margin to 20.7% in 2024 is a past example of this risk.

11

What to watch next

  1. Late January 2027

    Preliminary fourth-quarter 2026 results. A year earlier they were released on January 27, 2026. The points to check are whether fourth-quarter revenue holds near the third-quarter level and whether net income attributable to controlling shareholders extends its two-quarter decline.

  2. Late March 2027

    Filing of the 2026 annual report. The full-year confirmed revenue and operating margin, and whether the third-quarter preliminary figures were revised after audit review, are the points to verify.

  3. Mid-May 2027

    Preliminary first-quarter 2027 results. The first-quarter 2026 results were released on May 14, 2026. Export and online growth rates, and changes in the advertising expense ratio, are the points to check.

  4. Mid-August 2027

    Preliminary second-quarter 2027 results. The second-quarter 2026 results were released on August 14, 2026. The points to check are whether revenue holds near KRW 43.6 billion and whether the operating margin stays in the low-20 percent range.

12

Overall view

NeopharmCO's revenue has grown steadily since 2022, and second-quarter 2026 sales reached KRW 43.6 billion, which LS Securities described as the highest quarterly sales on record.

Third-quarter 2026 operating profit of KRW 10 billion rose 48.4% from a year earlier, but net income attributable to controlling shareholders fell to KRW 4.94 billion, so the operating and net profit trends diverge. Exports rose 50.0% in the second quarter of 2026, and online and offline channels grew together.

On the other side, a higher advertising expense ratio makes holding the operating margin a cost-structure challenge. On the financial side, total equity at the end of 2025 was KRW 195.4 billion and total liabilities were KRW 22.5 billion, with a debt-to-equity ratio of 11.5%.

Valuation can be read against past broker target multiples and the premium over net asset value. The next checkpoints are the preliminary fourth-quarter 2026 results and the full-year operating margin in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. vegannews.co.kr
  2. digitaltoday.co.kr
  3. investing.com
  4. comp.wisereport.co.kr
  5. catch.co.kr
  6. businesspost.co.kr
  7. seo.goover.ai
  8. kr.investing.com
  9. m.news.nate.com
  10. view.asiae.co.kr
  11. m.news.nate.com
  12. m.thinkpool.com
  13. news.nate.com
  14. rdata.kbsec.com
  15. judal.co.kr
  16. hanwhawm.com
  17. businesspost.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis